SG Americas Securities LLC Has $2.37 Million Holdings in Incyte Co. (NASDAQ:INCY)

SG Americas Securities LLC boosted its stake in Incyte Co. (NASDAQ:INCYFree Report) by 345.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 37,791 shares of the biopharmaceutical company’s stock after purchasing an additional 29,315 shares during the quarter. SG Americas Securities LLC’s holdings in Incyte were worth $2,373,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Clear Street Markets LLC raised its stake in Incyte by 93.6% in the first quarter. Clear Street Markets LLC now owns 362 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 175 shares in the last quarter. Parkside Financial Bank & Trust raised its stake in Incyte by 91.0% in the first quarter. Parkside Financial Bank & Trust now owns 447 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 213 shares in the last quarter. Salem Investment Counselors Inc. raised its stake in Incyte by 1,458.0% in the second quarter. Salem Investment Counselors Inc. now owns 779 shares of the biopharmaceutical company’s stock valued at $59,000 after purchasing an additional 729 shares in the last quarter. Sunbelt Securities Inc. acquired a new position in Incyte in the first quarter valued at about $71,000. Finally, Penserra Capital Management LLC raised its stake in Incyte by 9,866.7% in the second quarter. Penserra Capital Management LLC now owns 1,196 shares of the biopharmaceutical company’s stock valued at $74,000 after purchasing an additional 1,184 shares in the last quarter. Institutional investors and hedge funds own 92.61% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have commented on INCY. William Blair reissued an “outperform” rating on shares of Incyte in a research note on Tuesday, February 6th. Citigroup lowered their target price on Incyte from $82.00 to $81.00 and set a “buy” rating for the company in a research note on Wednesday, February 14th. Bank of America lowered their target price on Incyte from $69.00 to $67.00 and set a “neutral” rating for the company in a research note on Wednesday, March 13th. Mizuho lowered their target price on Incyte from $82.00 to $77.00 and set a “neutral” rating for the company in a research note on Thursday, December 14th. Finally, BMO Capital Markets boosted their target price on Incyte from $58.00 to $64.00 and gave the stock a “market perform” rating in a research note on Wednesday, February 14th. Eight equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $76.07.

Read Our Latest Stock Report on Incyte

Insider Activity at Incyte

In other Incyte news, EVP Vijay K. Iyengar sold 657 shares of the stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $65.00, for a total transaction of $42,705.00. Following the transaction, the executive vice president now directly owns 43,412 shares in the company, valued at approximately $2,821,780. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 17.50% of the stock is currently owned by company insiders.

Incyte Stock Performance

Shares of INCY stock opened at $56.55 on Wednesday. The business’s 50 day simple moving average is $59.32 and its 200 day simple moving average is $58.64. Incyte Co. has a one year low of $50.27 and a one year high of $76.04. The stock has a market capitalization of $12.70 billion, a PE ratio of 21.34, a PEG ratio of 1.22 and a beta of 0.65. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.55 and a quick ratio of 3.36.

Incyte (NASDAQ:INCYGet Free Report) last announced its earnings results on Tuesday, February 13th. The biopharmaceutical company reported $1.06 EPS for the quarter, missing the consensus estimate of $1.15 by ($0.09). Incyte had a net margin of 16.17% and a return on equity of 12.56%. The company had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1 billion. During the same quarter in the previous year, the company earned $0.44 earnings per share. The business’s revenue was up 9.3% on a year-over-year basis. As a group, research analysts forecast that Incyte Co. will post 3.85 earnings per share for the current year.

About Incyte

(Free Report)

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.

Featured Articles

Institutional Ownership by Quarter for Incyte (NASDAQ:INCY)

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.